目的: 探究异麦芽糖酐铁在维持性血液透析（maintenance hemodialysis,MHD）合并缺铁性贫血（（iron deficiency anemia,IDA）患者中应用的临床疗效。方法: 选取2021年6月—2022年6月在本院血液净化中心规律行MDH合并IDA患者61例,按照治疗药物的不同分为蔗糖铁组和异麦芽糖酐铁组,其中蔗糖铁组29例,异麦芽糖酐铁组32例。蔗糖铁组患者予蔗糖铁治疗,异麦芽糖酐铁组患者予异麦芽糖酐铁治疗。连续治疗3个月后,比较两组患者生化指标变化及不良反应发生情况。结果: 治疗前,两组患者各临床指标比较,差异均无统计学意义。治疗3个月后,两组患者血清尿素氮、血肌酐、尿酸、甲状旁腺素与治疗前比较无明显差异。两组患者血红蛋白、铁蛋白、转铁饱和度均高于治疗前,且异麦芽糖酐铁组高于蔗糖铁组,差异有统计学意义。同时,两组患者不良事件发生情况相比较,差异无统计学意义。结论: 在维持性血液透析合并缺铁性贫血患者中应用静脉铁剂治疗,异麦芽糖酐铁在维持血红蛋白及铁蛋白方面并不低于蔗糖铁,且显效更快,未增加不良反应发生率,值得临床推广应用。
Abstract
Objective To explore the clinical effificacy of Isomaltoside Iron in patients with maintenance hemodialysis (MHD) combined with iron defificiency anaemia (IDA). Methods 61patients with MDH combined with IDA in our hospital's blood purification center from June 2021 to June 2022 were selected and divided into sucrose iron group (29 cases) and isomaltoside iron group (32 cases) according to different treatment drugs. Patients in the sucrose iron group were treated with Sucrose Iron, while those in the isomaltoside iron group were treated with Isomaltoside Iron. After 3 months of continuous treatment, the changes in biochemical indicators (urea nitrogen, creatinine, PTH, hemoglobin, ferritin, transferrin saturation) and adverse reaction were compared between the two groups. Results Before treatment, there was no statistically significant difference between the clinical indicators of the two groups. After 3 months of treatment, there was no statistically significant difference in serum BUN, Scr, UA and PTH between the two groups. both the two groups had an increase in hemoglobin、ferritin and transferrin saturation levels, and the isomaltoside iron Group increased more significantly than sucrose iron group, which was statistically significant. At the same time, There is no statistically significant difference in the incidence of adverse events between the two groups of patients. Conclusion Compared with sucrose iron, isomaltoside iron induced a non-inferior haematological response, comparably low rates of hypersensitivity reactions, and exhibits faster effects, without increasing the incidence of adverse reactions。
关键词
血液透析 /
异麦芽糖酐铁 /
蔗糖铁 /
缺铁性贫血
Key words
hemodialysis /
isomaltoside iron /
sucrose iron /
iron-deficiency anemia
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] FERNADO V, HORLWALTER H, LAIN C M, et al.PRE-dialysis survey on anaemia management[J]. Nephrol Dial Transplant, 2003, 18(1): 89-100.
[2] ABOMHYA A, TAI W, AYAZ S, et al.Iron deficiency anemia: an overlooked complication of Crohn's disease[J]. J Hematol, 2022, 11(2): 55-61.
[3] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识 (2018修订版)[J]. 中华肾脏病杂志, 2018, 34(11): 860-866.
[4] 中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20): 1463-1502.
[5] 中华医学会血液学分会红细胞疾病盆血学组. 静脉铁剂应用中国专家共识 (2019 年版)[J]. 中华血液学杂志, 2019, 40(5): 358-362.
[6] 解玥, 张昭. 异麦芽糖酐铁、蔗糖铁和低分子右旋糖酐铁的临床价值比较[J]. 临床药物治疗杂志, 2021, 19(8): 29-33.
[7] 闫嘉, 赖学莉, 郭志勇. 静脉铁剂在腹膜透析患者中的应用[J]. 中国中西医结合肾病杂志, 2021, 22(6): 554-557.
[8] 王方海, 赵维, 陈建芳, 等. 补铁剂研究进展[J]. 药学进展, 2016, 40(9): 680-688.
[9] CREWS D C, BELLO A K, SAADI G, et al.Burden, access, and disparities in kidney disease[J]. Journal of Nephrology, 2019, 32(1): 1-8.
[10] ENE-LORDACHE B, PERICO N, BIKBOV B, et al.Chronic kidney disease and cardiovascular risk in xis regions of the world (ISN-KDDC): a cross-sectional study[J]. Lancet Glob Health, 2016, 4(5): 307-319.
[11] ZHANG L, WANG F, WANG L, et al.Prevalence of chronic kidney disease in China: a cross-sectional study[J]. Lancet, 2012, 379(9818): 815-822.
[12] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组. 慢性肾脏病筛查诊断及防治智囊[J]. 中国实用内科杂志, 2017, 37(1): 28-34.
[13] LIU J, ZHANG H, DIAO Z, et al.Epidemiological analysis of death among patients on maintenance hemodialysis: results from the beijing blood purification quality Control and Improvement Center[J]. BMC Nephrology, 2023, 24: 236.
[14] MACGINLEY R, WALKER R, IRVING M.KHA CARI Guideline: use of iron in chronic kidney disease patients[J]. Nephrology (Carlton), 2013, 18(12): 747-749.
[15] HSU CY, MCCULLOCH CE, CURHAN GC.Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey[J]. J Am Soc Nephrol, 2002, 13(2): 504-510.
[16] IO H, AIZAWA M, FUNABIKI K, et al.Impact of anaemia treatment for left ventricular remodelling prior to initiation of dialysis in chronic kidney disease patients: Efficacy and stability of long acting erythropoietin stimulating agents[J]. Nephrology (Carlton), 2015, 20(Suppl 4): 7-13.
[17] JESUS-SILVA JA, LAMPLUGH A, DHADA S, et al.Conversion of haemodialysis patients from iron sucrose to iron isomaltoside; a real -world experience[J]. BMC Nephrology, 2020, 21(1): 212.
[18] SUNIL B, KALRA P A, MARIO B, et al.Safety and efficacy ofiron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized. Ope-label, comparative trial[J]. Nephrol Dial Transplant, 2021, 36(1): 111-120.
[19] ZUO Q, WANG T, ZHU L, et al.A systemic review and meta-analysis on the efficacy and safety of ferumoxytol for anemia in chronic kidney disease patients[J]. Ren Fail, 2022, 44(1): 94-102.
[20] 高伟祺, 徐娜, 宋再伟, 等. 新型静脉铁剂的安全性: 一项系统评价再评价[J]. 临床药物治疗杂志, 2022, 20(12): 7-12.
基金
湖南省卫生健康委科研计划项目“异麦芽糖酐铁在中国尿毒症维持性人群中应用的真实世界研究”（D202303057573）
PDF(2343 KB)
